Scholars Central

Research articlePublished 6 May 2022

The Combination of Aluminum Adjuvant and CpG Adjuvant can Enhance the Immunogenicity of Recombinant HPV Vaccines

Authors: Jun Ge, Xiuying Pu, Juyin Li, Xiaoyu Xia, Xiao Dong Wang, Jiaojiao Sun, Changyao Tan, Tong Zhou, Jianhui Zhang, Srikanth Babu BMV, Bao Mengru, Xuan Liang, Jianqiang Li

1Department of Research and Development , Grand Theravac Life Sciences (Nanjing) Co. Ltd., Nanjing, China; 2Department of Life Sciences, Lanzhou University of Technology, Lanzhou, China; 3Department of Life Sciences, Jiangsu Argi-Animal Husbandry Vocational College, Jiangsu Province, China

Journal of Infectious Diseases & Therapy

Volume 10 · Issue 3 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Prophylactic vaccination and early detection of cervical cancers can effectively prevent Human Papilloma Virus (HPV) infection. HPV major capsid protein (HPV L1), a coat protein assembles into Virus-Like Particles (VLPs), acts as a potent immunogen. In the present investigational study, we evaluated the role of the combination effect of the aluminum adjuvant and TLR-9 agonist Cytosine phosphoguanine (CpG) on the immune response and the antigen dose-sparing effect. HPV L1 VLPs for types 16/18/52 and 58 have been produced by a gene expressed in Hansenula polymorpha. Bivalent (16,18) and tetravalent (16,18,52,58) vaccines with mono (Al+) and biadjuvanted (Al+CpG) were formulated by adsorbing purified VLPs onto aluminum hydroxide and CpG. Sera collected from immunized BALB/c mice showed that biadjuvanted vaccines elicits significantly higher anti-HPV neutralizing antibodies than monoadjuvanted vaccines. Full-dose biadjuvant vaccines (4 μg) elicits 2.5 times higher neutralizing antibodies than half-dose vaccine and no significant differences were observed between the full-dose monoadjuvant vaccine (Al+) and the half-dose biadjuvant vaccine (Al+CpG). Immunised mice have distinct levels of secreted IgG antibodies and the vaccines formulated with a aluminium and CpG, a TLR-9 agonist had skewed towards high Th1 biased immune response with an elevated IgG2a/IgG1 ratio. In conclusion, recombinant HPV vaccines formulated with an immune modulating CpG agonist and an adjuvant can induce a greater immune response. This combination of CpG and alum effectively reduces the dose of the HPV L1 vaccine by 2.5 times and makes the availability of vaccines at an affordable price.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Jun Ge”
  • BylineArticles whose byline prints “Xiuying Pu”
  • BylineArticles whose byline prints “Juyin Li”
  • BylineArticles whose byline prints “Xiaoyu Xia”
  • BylineArticles whose byline prints “Xiao Dong Wang”
  • BylineArticles whose byline prints “Jiaojiao Sun”
  • BylineArticles whose byline prints “Changyao Tan”
  • BylineArticles whose byline prints “Tong Zhou”